Table 5.

Features associated with progression from oligoarthritis to polyarthritis based on 128 patients (including dactylitis, enthesitis, and axial disease)a.

CovariateUnivariate AnalysisMultivariate Analysis
Full ModelReduced Model
HR (95% CI)PHR (95% CI)PHR (95% CI)P
Age, yrs1.01 (0.98–1.04)0.351.02 (0.99–1.04)0.18
PsA duration, yrs0.99 (0.86–1.13)0.860.96 (0.84–1.09)0.53
Sex (M vs F)0.90 (0.45–1.79)0.760.87 (0.46–1.62)0.66
LE SJ0.96 (0.40–2.34)0.930.83 (0.32–2.15)0.69
UE SJ1.81 (0.94–3.50)0.081.89 (0.94–3.78)0.07
LE LJ1.54 (0.76–3.13)0.231.73 (0.77–3.86)0.18
UE LJ1.37 (0.59–3.16)0.471.37 (0.58–3.23)0.48
Dactylitis1.32 (0.50–3.49)0.581.81 (0.63–5.24)0.27
Enthesitis1.68 (0.73–3.84)0.221.67 (0.68–4.07)0.26
Axial disease0.57 (0.20–1.61)0.290.64 (0.22–1.88)0.41
PASI1.02 (0.98–1.05)0.451.00 (0.97–1.05)0.67
HAQ2.14 (1.09–4.20)0.031.09 (0.40–3.01)0.86
SF-36 PCS0.96 (0.94–0.99)0.020.98 (0.94–1.02)0.30
SF-36 MCS0.97 (0.94–0.99)0.010.97 (0.94–1.00)0.060.97 (0.94–0.99)0.01
Elevated APR1.06 (0.58–1.87)0.840.99 (0.50–1.93)0.97
Highest medication
      NSAIDs0.60 (0.26–1.37)0.220.76 (0.31–1.86)0.54
      DMARDs1.13 (0.48–2.62)0.781.40 (0.54–3.62)0.49
      Biologics0.95 (0.33–2.73)0.921.29 (0.41–4.01)0.66
  • aBased on 128 patients with complete covariate information at each clinic visit (43 progressed to polyarthritis). APR: acute-phase reactant; DMARD: disease-modifying antirheumatic drug; HAQ-DI: Health Assessment Questionnaire-Disability Index; LE: lower extremity; LJ: large joint; MCS: mental component summary score; NSAID: nonsteroidal antiinflammatory drugs; PASI: Psoriasis Area Severity Index; PCS: physical component summary score; PsA: psoriatic arthritis; SF-36: 36-item Short Form Health Survey; SJ: small joint; UE: upper extremity.